“The tolerability, potential toxicities, target organs, and toxicokinetics of umbralisib were evaluated in repeat-dose toxicity studies up to 26 weeks in mice and 39 weeks in dogs.”
✓ VerifiedFDA multi-discipline review, p. 39Source ↗
Pivotal GLP studies
26-week mouse and 39-week dog oral studies
“The tolerability, potential toxicities, target organs, and toxicokinetics of umbralisib were evaluated in repeat-dose toxicity studies up to 26 weeks in mice and 39 weeks in dogs.”
✓ VerifiedFDA multi-discipline review, p. 39Source ↗
Route in tox
Oral (gavage in mice, capsule in dogs)
“The studies were conducted using the oral route of administration, which is consistent with the intended clinical route of administration.”
✓ VerifiedFDA multi-discipline review, p. 29Source ↗